Clinical Trials
60 trialsNCT06124157 2026-05-27
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT02981628 2026-05-04
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 2 Recruiting
NCT00558519 2026-04-29
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT07554482 2026-04-28
Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma
Beijing Tongren Hospital
Phase 2 Not yet recruiting
NCT02723994 2026-03-11
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Phase 2 Completed
NCT07457177 2026-03-09
Phaes â…¡ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL
Beijing Tongren Hospital
Phase 2 Not yet recruiting
NCT01574274 2026-02-05
SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT00501826 2026-01-07
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07227584 2025-11-12
ALL Backbone in AYAs
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT01920737 2025-09-16
A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04546399 2025-09-10
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT05660473 2025-08-01
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT00476190 2025-06-12
ALL Adult Consortium Trial: Adult ALL Trial
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03384654 2025-05-25
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Janssen Research & Development, LLC
Phase 2 Completed
NCT06034561 2025-05-16
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT02828358 2025-02-27
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
National Cancer Institute (NCI)
Phase 2 Completed
NCT06554626 2024-08-15
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT06210750 2024-05-17
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT04067518 2023-04-20
A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia
Servier
Phase 2 Completed
NCT01005914 2023-01-06
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01700946 2022-09-28
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT01451515 2022-06-28
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT02043587 2022-05-02
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
University of California, San Diego
Phase 2 Terminated
NCT05254899 2022-02-24
Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
ChineseAMS
Phase 2 Unknown
NCT04917250 2021-06-08
GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Beijing Tongren Hospital
Phase 2 Unknown
NCT04899414 2021-05-24
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
Peking University
Phase 2 Unknown
NCT04676789 2020-12-21
SPENT
Sun Yat-sen University
Phase 2 Unknown
NCT00671658 2020-12-03
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04405375 2020-05-28
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL
Beijing Tongren Hospital
Phase 2 Unknown
NCT04337593 2020-04-07
Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL
Beijing Tongren Hospital
Phase 2 Unknown
NCT04096690 2020-03-11
Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma
Ruijin Hospital
Phase 2 Unknown
NCT02918747 2020-01-28
PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage
Hunan Cancer Hospital
Phase 2 Unknown
NCT00866749 2019-09-10
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03318419 2019-08-20
Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia
Sun Yat-sen University
Phase 2 Unknown
NCT02535806 2019-08-13
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Children's Mercy Hospital Kansas City
Phase 2 Terminated
NCT02518750 2019-04-03
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01769209 2018-11-14
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Stanford University
Phase 2 Completed
NCT02419469 2018-06-11
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02533323 2018-05-09
P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens
Sun Yat-sen University
Phase 2 Terminated
NCT02419755 2018-03-07
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00882206 2017-12-28
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT02825147 2017-11-14
Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma
Ruijin Hospital
Phase 2 Completed
NCT00186875 2017-07-28
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00837200 2017-07-24
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Milton S. Hershey Medical Center
Phase 2 Terminated
NCT02660762 2017-06-19
Modified MRCUKALLâ…«/ECOGE2993 Regimen for ALL
Sun Yat-sen University
Phase 2 Unknown
NCT00973752 2017-03-30
Treatment of Older Adults With Acute Lymphoblastic Leukemia
Massachusetts General Hospital
Phase 2 Completed
NCT00873093 2017-01-27
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01991158 2016-06-14
GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma
Sun Yat-sen University
Phase 2 Unknown
NCT02080234 2016-04-20
Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL
Sun Yat-sen University
Phase 2 Unknown